Sigma-Aldrich Signs Agreement with SouthWest NanoTechnologies to Distribute SWeNT® Single-Wall Carbon Nanotubes
News Dec 04, 2008
Sigma-Aldrich and SouthWest NanoTechnologies Inc. (SWeNT) have announced that they have signed an agreement under which Sigma-Aldrich will distribute SWeNT's single-wall carbon nanotubes to the research and development community.
Under the terms of the agreement, Sigma-Aldrich will exclusively distribute research quantities of SWeNT® CG 100, SWeNT® SG 65 and SWeNT® SG 76 single-wall nanotubes globally through its Aldrich® division.
SWeNT will continue to work closely with industry partners to deliver commercial quantities of the materials and focus on commercial application development and large-scale production.
Single-wall carbon nanotubes consist of a hollow cylinder of carbon with a diameter equal to approximately one nanometer -- a billionth of a meter. Due to their unusual structure, single-wall nanotubes exhibit extraordinary optical and electronic properties, tremendous strength and flexibility, and high thermal and chemical stability.
"There are significant global market opportunities for single-wall carbon nanotubes, and Sigma-Aldrich has a world-class distribution network. This agreement will provide the best possible products and service to the research and development community, which is incorporating SWeNT carbon nanotubes into innovative, emerging technologies," said SWeNT CEO David Arthur.
"In our role as a leading producer of high-quality single-wall nanotubes, we are committed to being an innovative partner in Sigma-Aldrich's continued development and creative applications. This agreement is key to reaching that goal."
New Areas of the Brain Become Active After Students Learn PhysicsNews
Parts of the brain not traditionally associated with learning science become active when people are confronted with solving physics problems.READ MORE
Diamonds Could Decrease Cost of Imaging and Spectroscopy DevicesNews
A new approach shows great promise for enhancing the signal from magnetic resonance imaging (MRI) and nuclear magnetic resonance (NMR) using lasers without expensive magnets.
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018